This Article Free Full Text (Free PDF) Free References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by van der Wouden, E. A Articles by de Zeeuw, D. Search for Related Content PubMed PubMed Citation Articles by van der Wouden, E. A Articles by de Zeeuw, D. Social Bookmarking                         What's this?

Does Angiotensin (1-7) Contribute to the Antiproteinuric Effect of ACE-inhibitors?

Department of Clinical Pharmacology, University of Groningen, E.A.van.der.Wouden{at}med.umcg.nl

Robert H Henning

Department of Clinical Pharmacology, University of Groningen

Leo E Deelman

Department of Clinical Pharmacology, University of Groningen

Anton JM Roks

Department of Clinical Pharmacology, University of Groningen

Frans Boomsma

Department of Internal Medicine, Erasmus MC, Rotterdam, The Netherlands

Dick de Zeeuw

Department of Clinical Pharmacology, University of Groningen, Division of Nephrology, Groningen University Institute for Drug Exploration (GUIDE), University Medical Center Groningen, University of Groningen, Groningen, The Netherlands

Angiotensin-converting enzyme inhibitors (ACE-I) reduce proteinuria and protect the kidney in proteinuric renal disease. During ACE-I therapy, circulating levels of angiotensin (1-7) [Ang (1-7)] are increased. As cardiac and renal protective effects of Ang (1-7) have been reported, we questioned whether Ang (1-7) contributes to the antiproteinuric effects of ACE-I treatment.

Therefore, we evaluated whether Ang (1-7) infusion reduces proteinuria in a rat model of adriamycin-induced renal disease. In addition, the effect of a selective Ang (1-7) blocker, [D-Ala⁷]-Ang (1-7) (A779), was investigated in rats treated with the ACE-I, lisinopril (LIS). Six weeks after induction of proteinuria, therapy was started in four different groups: control, Ang (1-7), LIS, and LIS+A779. After two weeks, the rats were sacrificed. Six weeks after injection of adriamycin, the rats

had developed proteinuria of 323±40 mg/24 hours. The proteinuria remained stable in the control group and in the Ang (1-7) group, but was reduced in both LIS and LIS+A779-treated groups. Similarly, blood pressure (BP) was unchanged in the control and the Ang (1-7) groups, but reduced in both the LIS and the LIS+A779 groups. Plasma levels of Ang (1-7) were increased in the Ang (1-7) and in both LIS-treated groups.

We conclude that systemic Ang (1-7) plays no major role in the antiproteinuric and BPlowering effects of ACE-I in this rat model of adriamycin-induced nephrosis.

Key Words: Angiotensin (1-7) • ACE-inhibitors • Proteinuria • BP

Journal of Renin-Angiotensin-Aldosterone System, Vol. 6, No. 2, 96-101 (2005)
DOI: 10.3317/jraas.2005.016


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?